Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 298, Issue 3, 2010, Pages

  Halbirk, Mads ^a   Nørrelund, Helene ^b   Møller, Niels ^a   Holst, Jens Juul ^c   Schmitz, Ole ^a   Nielsen, Roni ^a   Nielsen Kudsk, Jens Erik ^a   Nielsen, Søren Steen ^a   Nielsen, Torsten Toftegaard ^a   Eiskjær, Hans ^a   Bøtker, Hans Erik ^a   Wiggers, Henrik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b VIBORG HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Insulin resistance; Metabolism; Nondiabetics

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOOP DIURETIC AGENT; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PLACEBO; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; BODY WEIGHT; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; EXERCISE TEST; FEMALE; GLUCOSE BLOOD LEVEL; HEART FUNCTION; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART OUTPUT; HEART RATE; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; ISCHEMIC HEART DISEASE; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TISSUE DOPPLER IMAGING; VOMITING;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIAC OUTPUT; CHRONIC DISEASE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXERCISE TOLERANCE; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEART FAILURE; HEART RATE; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INSULIN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 77749273703     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00930.2009     Document Type: Article

References (36)

1. Agostoni P, Cattadori G, Apostolo A, Contini M, Palermo P, Marenzi G, Wasserman K. Noninvasive measurement of cardiac output during exercise by inert gas rebreathing technique: a new tool for heart failure evaluation. J Am Coll Cardiol 46: 1779-1781, 2005.
2. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in Type 2 diabetes. J Clin Endocrinol Metab 89: 2078-2084, 2004.
3. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptordependent and -independent pathways. Circulation 117: 2340-2350, 2008.
4. Bentzen H, Pedersen RS, Nyvad O, Pedersen EB. Effect of exercise on natriuretic peptides in plasma and urine in chronic heart failure. Int J Cardiol 93: 121-130, 2004.
5. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 47: 1643-1649, 1998.
6. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 19: 580-586, 1996.
7. Dai H, Gustavson SM, Preston GM, Eskra JD, Calle R, Hirshberg B. Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects. Diabetes Obes Metab 10: 506-513, 2008.
8. Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, Johnson JA. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 335: 497-501, 2007.
9. Hansen BF, Jensen P, Nepper-Christensen E, Skjølstrup B. Effects of glucagon-like peptide-1 (7-36)amide on insulin stimulated rat skeletal muscle glucose transport. Acta Diabetol 35: 101-103, 1998.
10. Holst JJ. Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab 10: 229-235, 1999.
11. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28: 1083-1091, 2005.
12. Lommi J, Kupari M, Yki-Jarvinen H. Free fatty acid kinetics and oxidation in congestive heart failure. Am J Cardiol 81: 45-50, 1998.
13. Luque MA, Gonzalez N, Marquez L, Acitores A, Redondo A, Morales M, Valverde I, and Villanueva-Penacarrillo ML. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. J Endocrinol 173: 465-473, 2002.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
15. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741-744, 1993.
16. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, Shannon RP. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110: 955-961, 2004.
17. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109: 962-965, 2004.
18. Norrelund H, Wiggers H, Halbirk M, Frystyk J, Flyvbjerg A, Botker HE, Schmitz O, Jorgensen JO, Christiansen JS, Moller N. Abnormalities of whole body protein turnover, muscle metabolism and levels of metabolic hormones in patients with chronic heart failure. J Intern Med 260: 11-21, 2006.
19. Nystrom T. The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Horm Metab Res 40: 593-606, 2008.
20. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43: 535-539, 1994.
21. Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail 1: 153-160, 2008.
22. Smooke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 149: 168-174, 2005.
23. Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ Jr, Maher TD, Dean DA, Bailey SH, Marrone G, Benckart DH, Elahi D, Shannon RP. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 100: 824-829, 2007.
24. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagonlike peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12: 694-699, 2006.
25. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85: 1093-1129, 2005.
26. Suskin N, McKelvie RS, Burns RJ, Latini R, Pericak D, Probstfield J, Rouleau JL, Sigouin C, Solymoss CB, Tsuyuki R, White M, Yusuf S. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J 21: 1368-1375, 2000.
27. Swan JW, Anker SD, Walton C, Godsland IF, Clark AL, Leyva F, Stevenson JC, Coats AJ. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 30: 527-532, 1997.
28. Taegtmeyer H. Cardiac metabolism as a target for the treatment of heart failure. Circulation 110: 894-896, 2004.
29. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22: 1137-1143, 1999.
30. Tuunanen H, Engblom E, Naum A, Nagren K, Hesse B, Airaksinen KEJ, Nuutila P, Iozzo P, Ukkonen H, Opie LH, Knuuti J. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 114: 2130-2137, 2006.
31. Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG, Holst JJ. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88: 2706-2713, 2003.
32. Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP, Verhoeven R, Buganova I, Madsbad S. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30: 1608-1610, 2007.
33. Wiggers H, Norrelund H, Nielsen SS, Andersen NH, Nielsen-Kudsk JE, Christiansen JS, Nielsen TT, Moller N, Botker HE. Influence of insulin and free fatty acids on contractile function in patients with chronically stunned and hibernating myocardium. Am J Physiol Heart Circ Physiol 289: H938-H946, 2005.
34. Wilken M, Larsen FS, Buckley D, Holst JJ. New highly specific immunoassays for glucagon-like peptide-1 (GLP-1) (Abstract). Diabetologia 42, Suppl 1: A196, 1999.
35. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359: 824-830, 2002.
36. Zinman B, Hoogwerf BJ, Duran GS, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 146: 477-485, 2007.